Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.

Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have ...

Gilead Sciences’ seladelpar has been recommended by the European Medicines Agency’s human medicines committee to treat the ...

It was a busy week in the biotech sector with lots of regulatory and pipeline updates. Among bigwigs, Gilead Sciences, Inc.

Recall that seladelpar's FDA approval for primary biliary cholangitis [PBC] was expected in August and would open a ~$3 billion PBC market up to Gilead. Let's see how things have played out since ...

Credit: Collagery/Shutterstock. Gilead Sciences has entered a strategic partnership with Terray Therapeutics for the discovery and development of small-molecule therapies across several targets. The ...

In other recent news, Gilead Sciences has received positive feedback from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for seladelpar, a treatment for ...

Details are thin on the ground, but we know Gilead is tapping into Terray’s so-called tNova platform, the startup’s generative AI. This platform is designed to improve the speed, cost and ...